Edwards Lifesciences Corporation (EW)

Environment story

Edwards Lifesciences has disclosed limited quantitative environmental data. The company acknowledges climate change risks in its 10-K filings but has not disclosed Scope 1, 2, or 3 GHG emissions figures or a net-zero target year. Environmental & Health/Safety regulations compliance is mentioned as an ongoing cost driver, but no major environmental controversies or fines are reported in the 2025 filings. The company's medical device manufacturing (pericardial tissue valves using bovine tissue) carries a regulatory risk linked to animal-borne disease concerns, though no material adverse impact has been experienced to date. The absence of disclosed emissions targets and baseline emissions data results in significant scoring deductions per the deterministic rubric.

Social story

Edwards Lifesciences reports a strong commitment to human capital management and talent retention through leadership development, performance reviews, and succession planning. The company has appointed an internal candidate (Bernard Zovighian) as CEO, demonstrating a robust succession pipeline. Board diversity is stated as a strategic priority, with directors possessing multiple competencies including human capital management. However, quantitative diversity metrics (% women, % underrepresented racial/ethnic groups in workforce and executive leadership) are not disclosed in the 10-K or proxy statement. CEO-to-median-worker pay ratio is not disclosed. No documented union suppression activities or major strikes within the past 24 months are reported. Supply-chain ethics and labor practices in manufacturing and vendor networks are not detailed. The lack of disclosed diversity percentages and CEO-to-worker pay ratio limits scoring precision but does not reveal active anti-labor conduct.

Governance story

Edwards Lifesciences demonstrates strong governance practices with 8 of 9 directors (89%) independent, exceeding the 75% threshold. The company has eliminated dual-class share structures, supermajority voting provisions, and adopted proxy access rights (3% ownership, 3-year holding). An independent director serves as Board Chair (since 2024), with clear separation of CEO and Board Chair roles. The company maintains annual director elections with majority voting standards, comprehensive director evaluation processes, and stock ownership guidelines. Board committees (Audit and Compensation & Governance) are fully independent. However, specific lobbying expenditures targeting environmental deregulation or consumer-protection rollbacks are not disclosed, and no antitrust, significant consumer-safety, or financial-fraud regulatory proceedings are reported in the 2025 filings. The company engages proactively with stockholders (57% of shares contacted since 2025 annual meeting; 36% engaged) and has amended bylaws in response to shareholder feedback.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Edwards Lifesciences Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Edwards Lifesciences Corporation in the app for interactive charts and portfolio building.

More in Healthcare